FY2018 Earnings Estimate for Acorda Therapeutics, Inc. (ACOR) Issued By Oppenheimer Holdings

Acorda Therapeutics, Inc. (NASDAQ:ACOR) – Equities researchers at Oppenheimer Holdings boosted their FY2018 earnings per share (EPS) estimates for Acorda Therapeutics in a research note issued on Wednesday. Oppenheimer Holdings analyst J. Olson now anticipates that the biopharmaceutical company will post earnings of ($0.50) per share for the year, up from their prior estimate of ($0.97). Oppenheimer Holdings has a “Hold” rating and a $18.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Acorda Therapeutics’ FY2019 earnings at ($1.56) EPS, FY2020 earnings at ($1.85) EPS and FY2021 earnings at $0.16 EPS.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.26). The firm had revenue of $141.07 million for the quarter, compared to analyst estimates of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The company’s revenue was up 4.0% compared to the same quarter last year. During the same period last year, the business earned ($0.04) EPS.

WARNING: “FY2018 Earnings Estimate for Acorda Therapeutics, Inc. (ACOR) Issued By Oppenheimer Holdings” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/21/fy2018-earnings-estimate-for-acorda-therapeutics-inc-acor-issued-by-oppenheimer-holdings.html.

Other research analysts also recently issued reports about the company. Cowen and Company reaffirmed a “buy” rating and set a $35.00 target price on shares of Acorda Therapeutics in a report on Tuesday, August 29th. Stifel Nicolaus reaffirmed a “buy” rating and set a $26.00 target price (down from $30.00) on shares of Acorda Therapeutics in a report on Thursday, August 31st. HC Wainwright started coverage on Acorda Therapeutics in a report on Wednesday, November 8th. They set a “buy” rating and a $35.00 target price on the stock. TheStreet downgraded Acorda Therapeutics from a “c-” rating to a “d+” rating in a report on Friday. Finally, Zacks Investment Research raised Acorda Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Acorda Therapeutics has a consensus rating of “Hold” and an average target price of $21.43.

Shares of Acorda Therapeutics (NASDAQ ACOR) traded up $0.60 on Monday, reaching $20.10. The company’s stock had a trading volume of 1,123,006 shares, compared to its average volume of 945,901. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77.

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Acorda Therapeutics by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 4,139,589 shares of the biopharmaceutical company’s stock worth $86,931,000 after buying an additional 233,575 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Acorda Therapeutics by 8.1% in the 1st quarter. Geode Capital Management LLC now owns 440,824 shares of the biopharmaceutical company’s stock worth $9,256,000 after buying an additional 33,030 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Acorda Therapeutics by 21.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,831,450 shares of the biopharmaceutical company’s stock worth $38,474,000 after buying an additional 323,888 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Acorda Therapeutics by 0.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 387,668 shares of the biopharmaceutical company’s stock worth $8,142,000 after buying an additional 2,714 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Acorda Therapeutics by 48.3% in the 1st quarter. AQR Capital Management LLC now owns 129,458 shares of the biopharmaceutical company’s stock worth $2,719,000 after buying an additional 42,154 shares during the last quarter.

In related news, major shareholder Scopia Capital Management Lp purchased 766,201 shares of the business’s stock in a transaction on Tuesday, August 29th. The stock was acquired at an average price of $19.23 per share, for a total transaction of $14,734,045.23. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 7.90% of the company’s stock.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply